Morgan Stanley Maintains Overweight on NICE, Lowers Price Target to $130

Benzinga Newsdesk www.benzinga.com Negative 81.7%

Neg 81.7% Neu 0% Pos 0%

Morgan Stanley analyst Hamza Fodderwala maintains NICE (NASDAQ:NICE) with a Overweight and lowers the price target from $148 to $130.